Publikationen, an denen er mitarbeitet Alba Vicente Blázquez (10)

2023

  1. Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  2. Novel amino analogs of the trimethoxyphenyl ring in potent colchicine site ligands improve solubility by the masked polar group incorporation (MPGI) strategy

    Bioorganic Chemistry, Vol. 131

2021

  1. Methoxy and bromo scans on N-(5-methoxyphenyl) methoxybenzenesulphonamides reveal potent cytotoxic compounds, especially against the human breast adenocarcinoma MCF7 cell line

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 36, Núm. 1, pp. 1029-1047

  2. Methylsulfanylpyridine based diheteroaryl isocombretastatin analogs as potent anti-proliferative agents

    European Journal of Medicinal Chemistry, Vol. 209

  3. Microtubule destabilizing sulfonamides as an alternative to taxane-based chemotherapy

    International Journal of Molecular Sciences, Vol. 22, Núm. 4, pp. 1-21

  4. New indolesulfonamide derivatives targeting the colchicine site of tubulin: synthesis, anti-tumour activity, structure–activity relationships, and molecular modelling

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 36, Núm. 1, pp. 2025-2044

2020

  1. Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring

    Bioorganic Chemistry, Vol. 98

2019

  1. Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target

    Medicinal Research Reviews, Vol. 39, Núm. 3, pp. 775-830

  2. Diseño, síntesis y evaluación de amidas y sulfonamidas con actividad tipo colchicina contra Strongyloides venezuelensis

    XI Congreso de la Sociedad Española de Medicina Tropical y Salud Internacional (SEMTSI)

  3. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors

    Molecules (Basel, Switzerland), Vol. 24, Núm. 23